Editorial [Hot Topic: New Treatment Strategy of the Myelodysplastic Syndromes]
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3147-3148
Author(s):
Kaoru Tohyama
World Health Organization Classification of Myelodysplastic Syndromes
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3149-3162
Author(s):
Magdalena Czader and Attilio Orazi
Implication of microRNAs in the Pathogenesis of MDS
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3170-3179
Author(s):
Jing Fang, Melinda Varney and Daniel T. Starczynowski
Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3190-3197
Author(s):
Kaoru Tohyama
Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3222-3234
Author(s):
Norbert Gattermann
Transfusion-related Acute Lung Injury: An Overview
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3236-3240
Author(s):
Behnaz Bayat and Ulrich J. Sachs
Prevention of Immune-mediated Transfusion-related Acute Lung Injury; from Bloodbank to Patient
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3241-3248
Author(s):
Marcella C.A. Muller, Leendert Porcelijn and Alexander P.J. Vlaar
Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor
Journal:
Current Pharmaceutical Design
Volume:
18
Page:
3255-3259
Author(s):
Michael A. Ellison, Daniel R. Ambruso and Christopher C. Silliman
Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Journal:
Current Molecular Medicine
Volume:
12
Page:
746-762
Author(s):
L. Muinelo-Romay, L. Alonso-Alconada, M. Alonso-Nocelo, J. Barbazan and M. Abal
Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Journal:
Current Molecular Medicine
Volume:
12
Page:
788-803
Author(s):
S. Nowsheen, A. C. Whitley and E. S. Yang